{Reference Type}: Journal Article
{Title}: Effects on calcium phosphate homeostasis after sodium-glucose cotransporter 2 inhibitor in patients with advanced chronic kidney disease and type 2 diabetes mellitus.
{Author}: Chan GCK;Ng JKC;Szeto CC;Chow KM;
{Journal}: Diabetes Res Clin Pract
{Volume}: 216
{Issue}: 0
{Year}: 2024 Aug 14
{Factor}: 8.18
{DOI}: 10.1016/j.diabres.2024.111818
{Abstract}: <B>BACKGROUND: </B>The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on calcium phosphate homeostasis in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) remain uncertain.<BR><B>METHODS: </B>A retrospective observational cohort study of patients with T2DM at CKD stage G3b-5ND who received SGLT2i as compared to control from 1 January 2015 through 31 December 2021 was recruited. Propensity score assignment at 1:3 ratio by logistic regression was done. All patients were followed for 12 months. Outcomes were changes in phosphate level.<BR><B>RESULTS: </B>We analyzed 1,450 SGLT2i users and 4,350 control subjects. At the 12th month, SGLT2i users had a slower increase in phosphate levels (absolute change: -0.01 ± 0.28 vs + 0.14 ± 0.34 mmol/L; percentage change: -0.74 % ± 25.56 vs + 10.88 ± 28.15 %, P for both < 0.001). The proportion of patients with high phosphate was lower with SGLT2i (8.2 % vs 24.6 % increase). In the generalized estimating equation, SGLT2i was linked to a longitudinal reduction in phosphate (B -0.039, P<0.001).<BR><B>CONCLUSIONS: </B>SGLT2i can effectively slow down the progression of phosphate retention in advanced CKD with T2DM.